Methods for culture and production of single cell populations of human embryonic stem cells (HESCS)
We used ACCUTASE®, a commercially available cell detachment solution, for single cell propagation of pluripotent hESCs. Unlike trypsin dissociation, ACCUTASE® treatment does not significantly affect the plating efficiency of hESC dissociation into single cells. Cultures dissociated with ACCUTASE® to single cells at each passage maintain a higher proportion of pluripotent cells as compared to collagenase-passaged hESCs. ACCUTASE®-treated hESCs can be grown to a high density as monolayers, and yet retain their pluripotency.
1. A method for analyzing a plurality of primate pluripotent stem cells comprising:
(a) obtaining a population comprising primate pluripotent stem cells in a bioreactor;
(b) disassociating the primate pluripotent stem cells into a plurality of single primate pluripotent stem cells with a mixture of enzymes with proteolytic, collagenolytic, and DNAse activities, wherein 75% to 90% of the single primate pluripotent stem cells are viable; and
(c) analyzing the plurality of single primate pluripotent stem cells.
2. The method of claim 1 , wherein the single primate pluripotent stem cells are in suspension.
3. The method of claim 1 , wherein the single primate pluripotent stem cells are karyotypically normal.
4. The method of claim 1 , wherein the single primate pluripotent stem cells maintain proliferative capacity from the first day in culture.
5. The method of claim 1 , wherein the single primate pluripotent stem cells do not experience a decrease in plating efficiency.
6. The method of claim 1 , wherein the single primate pluripotent stem cells are human.
7. The method of claim 6 , wherein the human cells are human embryonic stem cells.
8. A composition comprising a mixture of enzymes with proteolytic, collagenolytic, and DNAse activities and a plurality of disassociated single primate pluripotent stem cells in a bioreactor, wherein 75% to 90% of the single primate pluripotent stem cells are viable.
9. The composition of claim of 8 , wherein the single primate pluripotent stem cells are karyotypically normal.